

7 October 2024

Enlitic secures new customers & a new reseller agreement

Highlights

- Enlitic is pleased to announce two new customers of Enlitic's distribution partners for its ENDEX solution:
 - DMC Healthcare, a leading independent provider of dermatology, radiology reporting and endoscopy services, signed as a customer of Biotronics 3D, Enlitic's distribution partner
 - National Cancer Center Japan, the largest cancer research hub in Japan, signed as a customer of Clairvo Technologies, Enlitic's distribution partner
 - New reseller partnership with UltraRAD, leading software solutions and cloud-based services provider to radiologists and hospitals in the United States
-

Enlitic, Inc. (ASX: ENL) ("the Company") is pleased to announce two new customers and one new reseller agreement for its ENDEX solution, demonstrating growing commercial momentum.

DMC Healthcare - Enlitic welcomes independent healthcare provider DMC Healthcare Limited in the United Kingdom as a customer via its distribution partnership with Biotronics 3D. DMC Healthcare currently works with more than 30 National Health Service organisations to provide dermatology, radiology reporting and endoscopy services to up to 100,000 patients each year. DMC Healthcare has entered into a three-year contract with Enlitic's distribution partner, Biotronics 3D to use ENDEX for AI Orchestration and Radiology Workflow improvement.

National Cancer Center Japan - The Company also welcomes National Cancer Center Japan (NCC) as a customer via its distribution partnership with Clairvo Technologies. NCC is Japan's largest cancer research center and is consistently listed as one of the world's best specialised hospitals. NCC has entered into a five-year agreement with Enlitic's distribution partner, Clairvo Technologies to leverage Enlitic's ENDEX for Radiology Workflow.

UltraRAD - Enlitic has signed a three-year reseller agreement with UltraRAD Corporation, a leading healthcare software solutions and cloud-based services provider in the United States. Partnering with GE, Fujifilm and Nuance, it develops software for radiologists, teleradiology service providers, private practices, imaging centers and hospitals. UltraRAD is licensed to distribute ENDEX Radiology Workflow to its US market customers, broadening Enlitic's customer acquisition channels in the US.

Michael Sistenich, CEO of Enlitic, said "We continue to make good commercial progress, as evidenced by our new customers DMC Healthcare in the UK and National Cancer Center Japan, via

our established distribution partnership with Biotronics 3D and Clairvo Technologies, respectively. This validates our business model to reach customers through channel partners as well as through direct relationships. As our commercial pace continues to accelerate, we are excited to partner with UltraRAD Corporation to reach their US customers.”

While each of these new agreements are not considered material in respect of their terms and conditions or in respect of their financial impact for Enlitic, they evidence the progress that the Company is making in respect of its business model.

– ENDS –

This announcement was authorised for release by the Board of Enlitic, Inc.

Enquiries

Enlitic Investor Relations

Australia:
invest_au@enlitic.com

USA:
invest@enlitic.com

About Enlitic

Enlitic is a software company that uses artificial intelligence to develop software products that manage medical imaging data in radiology (such as MRI, CT scans, X-ray and ultrasound images) and licences such products to healthcare providers. Enlitic’s products (including its current product offering and product suite under development) seek to standardise, protect, integrate, and analyse data to create the foundation of a real-world evidence platform that can improve clinical workflows, increase efficiencies, and expand capacity. Read more at enlitic.com.

Forward looking statements

This announcement may contain certain forward-looking statements, forecasts, estimates, projections and comments about future events, including the Company's beliefs, assumptions and expectations about the performance of its businesses and certain strategic transactions and the recovery of domestic and global airline booking levels. Forward looking statements can generally be identified by the use of forward-looking words such as, "expect", "anticipate", "likely", "intend", "should", "could", "may", "predict", "plan", "propose", "will", "believe", "forecast", "estimate", "goals", "aims", "target" and other similar expressions. Indications of, and guidance or outlook on, future earnings or financial position or performance are also forward-looking statements. Forward looking statements involve inherent risks and uncertainties, both general and specific, and there is a risk that such predictions, forecasts, projections and other forward-looking statements will not be achieved. A number of important factors, both known and unknown, could cause the Company's actual results to differ materially from the plans, objectives, expectations, estimates and intentions expressed in such forward-looking statements, and many of these factors are beyond the Company's control, and may involve significant elements of subjective judgement and assumptions as to future events which may or may not be correct. As such, there can be no assurance that actual outcomes

will not differ materially from these statements. There are usually differences between forecast and actual results because events and actual circumstances frequently do not occur as forecast and their differences may be material.